Roche Holding AG Logo

Roche Holding AG

A global leader in pharmaceuticals and diagnostics, pioneering personalized healthcare solutions.

RO | SW

Overview

Corporate Details

ISIN(s):
CH0012032048 (+1 more)
LEI:
549300U41AUUVOAAOB37
Country:
Switzerland
Address:
Grenzacherstr. 124, 4058 Basel
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Roche Holding AG is a global, research-based healthcare company operating through two primary divisions: Pharmaceuticals and Diagnostics. As one of the world's largest biotechnology companies, Roche is a leading provider of innovative cancer treatments and a key developer of medicines for viral infections and cardiometabolic diseases. The Diagnostics division focuses on providing in-vitro diagnostic tests and transformative solutions that support early detection, prevention, diagnosis, and treatment monitoring. By combining its strengths in both pharmaceuticals and diagnostics, Roche aims to advance personalized healthcare and improve patient outcomes worldwide through scientific innovation and digital health solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2004-12-31 00:00
Annual Report
Annual Report 2004
English 8.5 MB
2004-12-31 00:00
Annual Report
Jahresbericht 2004
German 8.8 MB
2004-04-22 00:00
Investor Presentation
Presentation to analysts First Quarter 2004 Basle, April 21, 2004
English 1.2 MB
2003-12-31 00:00
Annual Report
Annual Report 2003
English 8.4 MB
2003-12-31 00:00
Annual Report
Jahresbericht 2003
German 8.5 MB
2003-07-25 00:00
Investor Presentation
First Half 2003 Presentation to analysts
English 1.1 MB
2003-04-11 00:00
Investor Presentation
26 March 2003Roadshow USANew York
English 175.9 KB
2003-04-10 00:00
Investor Presentation
Company Presentation 2003
English 250.3 KB
2003-02-12 00:00
Investor Presentation
16 January 2003 Roadshow Germany
English 323.7 KB
2002-12-31 00:00
Annual Report
Annual Report 2002
English 9.3 MB
2002-12-31 00:00
Annual Report
Jahresbericht 2002
German 9.7 MB

Automate Your Workflow. Get a real-time feed of all Roche Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Roche Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Roche Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-16 N/A Executive member Sell None 1,494,248.20 CHF
2025-02-07 N/A Non-Executive member Buy None 613,652.00 CHF
2024-07-26 N/A Non-Executive member Sell None 1,743,760.00 CHF
2024-07-25 N/A Non-Executive member Sell None 723,460.00 CHF
2024-06-21 N/A Executive member Sell None 2,220,432.00 CHF
2024-06-10 N/A Executive member Sell None 1,260,138.00 CHF
2024-05-29 N/A Non-Executive member Buy None 504,400.00 CHF

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.